Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal unchange5.810 0.000 (0.000%)
Others

12/01/2018 17:43

[I-bank focus]Credit Suisse ups CSPC Pharma (01093) to HK$22

[ET Net News Agency, 12 January 2018] Credit Suisse lifted its target price for CSPC
Pharmaceutical (01093) to HK$22 from HK$18.4, and maintained its "outperform" rating.
The research house believes CSPC will deliver the strongest organic growth among the
large pharma names and near-term profitability. In 2018, the new NDRL inclusion of NBP
injection and Jinyouli will have a full-year impact, which Credit Suisse estimated to
deliver 40%/70% growth respectively.
It sees the company to achieve 19.5% sales CAGR in 2017-19, with 17.3% organic growth
CAGR. Credit Suisse said CSPC's albumin-bounded paclitaxel, metformin, and clopidogrel
hydrogen sulphate have all been included in the drug priority review list and could start
contributing to sales in early 2018. (KL)

Back to Others

Remark: Real time quote last updated: 18/04/2024 08:40
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.